Tacrolimus ========== Ointment 1 mg per g, 30 g SaveGeneral schedule PBS item code15542BMaximum quantity1 units Repeats1 More detailsProgramGE AdministrationAPPLICATION Benefit typeA Brands - aZematop[TGA record](https://www.tga.gov.au/resources/artg/388172 "TGA ARTG record 388172")[CMI (PDF)](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2025-CMI-02276-1 "Consumer Medicine Information (PDF)")[PI (PDF)](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2025-PI-02275-1 "Product Information (PDF)") Dispensed price for maximum quantity (DPMQ)3 pricesaZematop · Community pharmacy$54.27 aZematop · Private hospital$49.71 aZematop · Public hospital$39.91 Restrictions & indications ------------------------------ AUTHORITY REQUIRED Moderate To Severe Atopic Dermatitis - Flare treatment Show full PBS criteriaHide full PBS criteriaModerate to severe atopic dermatitis Flare treatment Patient must have 1 or more of the following contraindications to topical corticosteroids: (i) perioral dermatitis; (ii) periorbital dermatitis; (iii) rosacea; (iv) epidermal atrophy; (v) dermal atrophy; (vi) allergy to topical corticosteroids; (vii) cataracts; (viii) glaucoma; (ix) raised intraocular pressure; or The condition must not have been adequately controlled with topical corticosteroid therapy. Inadequate control of this condition with topical corticosteroid therapy is defined as: (i) no clearance of the skin despite at least 2 weeks of a potent topical corticosteroid for the body or a mild topical corticosteroid for the face and eyelids, applied every day; or (ii) clearing of the skin with at least 2 weeks of a potent topical corticosteroid for the body or a mild topical corticosteroid for the face and eyelids, applied every day, but almost immediate and significant flare in disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions. Treatment should be discontinued, and further treatment options should be considered if no signs of improvement are seen after 2 weeks of treatment. Once clearance or near clearance of atopic dermatitis is achieved, patients should cease tacrolimus treatment and reinitiate only if there is a flare of their atopic dermatitis that meets the PBS eligibility criteria. Notes (3)Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS) or by telephone by contacting Services Australia on 1800 888 333. No increase in the maximum quantity or number of units may be authorised. No increase in the maximum number of repeats may be authorised. Prescribing notes (3)No increase in the maximum quantity or number of units may be authorised. No increase in the maximum number of repeats may be authorised. Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS) or by telephone by contacting Services Australia on 1800 888 333. Data source: [Australian Government PBS Schedule](https://www.pbs.gov.au/info/browse/download) · Record updated 30 September 2026. Verify current listing and prescribing requirements on the [official PBS website](https://www.pbs.gov.au/).